Ph.D. Jay R. Luly - 01 Dec 2025 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role: President and CEO, Director
Signature: /s/ Matthew Kowalsky as attorney-in-fact
Issuer symbol: ENTA
Transactions as of: 01 Dec 2025
Net transactions value: -$26,616
Form type: 4
Filing time: 03 Dec 2025, 16:34:07 UTC
Previous filing: 26 Nov 2025
Next filing: 05 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Luly Jay R.	President and CEO, Director	C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN	/s/ Matthew Kowalsky as attorney-in-fact	03 Dec 2025	0001571211

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ENTA	Common Stock	Tax liability	$26,616	-1,885	-0.22%	$14.12	862,769	01 Dec 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021.